Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateTopicCOVID-19MedicinesVaccinesReferralsAdvanced therapiesAntimicrobial resistanceBiologicalsBiosimilarsBrexitCareersClinical trialsCompassionate useCompliance and inspectionsCorporateData on medicinesEarly accessFeesGeneric and hybrid medicinesGovernanceInnovationMaximum residue limitMedication errorMedicines for use outside the EUMedicine shortagesMpoxPaediatricsParallel distributionPharmacovigilanceProcurementProduct informationQuality of medicinesRare diseasesRegulatory and procedural guidanceResearch and developmentScientific adviceScientific guidelinesSMEVeterinary limited marketsDiseases areaViral diseasesCancerDiabetesHIV and AIDSImmune-system diseasesCardiovascular diseasesNeurodegenerative diseasesTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPManagement BoardPDCOCATCMDhCOMPCVMPHMPCPRACPatient safetyYesFiltersResults (8) NuvaxovidSort byLast update date (new to old)Last update date (old to new)A-ZZ-AEMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.531 October 2023NewsHumanCOVID-19VaccinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 202222 September 2022NewsHumanCOVID-19MedicinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 202224 June 2022NewsHumanCOVID-19MedicinesReferralsEMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 1723 June 2022NewsHumanCOVID-19VaccinesEMA Management Board: highlights of March 2022 meeting18 March 2022NewsCorporateEMA recommends Nuvaxovid for authorisation in the EU20 December 2021NewsHumanCOVID-19VaccinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19MedicinesEMA receives application for conditional marketing authorisation of Novavax’s COVID-19 vaccine, Nuvaxovid17 November 2021NewsHumanCOVID-19Medicines
EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.531 October 2023NewsHumanCOVID-19Vaccines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 202222 September 2022NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 202224 June 2022NewsHumanCOVID-19MedicinesReferrals
EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 1723 June 2022NewsHumanCOVID-19Vaccines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 202117 December 2021NewsHumanCOVID-19Medicines
EMA receives application for conditional marketing authorisation of Novavax’s COVID-19 vaccine, Nuvaxovid17 November 2021NewsHumanCOVID-19Medicines